Venous thromboembolic events (VTE) have become a global public health burden, with the global low molecular weight heparin (LMWH) market projected to reach USD 5.52 billion by 2031 at a CAGR of 5.3%. As two core LMWH products, Enoxaparin Sodium and Dalteparin Sodium occupy crucial market shares—Enoxaparin Sodium accounts for 26.8% of China’s LMWH market, while Dalteparin Sodium holds 15.5% , serving diverse clinical needs from orthopedic postoperative prophylaxis to hemodialysis anticoagulation. For global buyers, the biggest concerns lie in Enoxaparin Sodium price volatility, inconsistent Dalteparin Sodium quality, and fragmented supply of dual products. Choosing a supplier with stable pricing, reliable quality and integrated supply capacity is critical to reducing procurement risks.

　　Jiulong, a leading pharmaceutical enterprise specializing in anticoagulant drugs, stands out with integrated solutions for Enoxaparin Sodium price stability and Dalteparin Sodium quality assurance. Adhering to the concept of "stable pricing for win-win, quality for trust", Jiulong addresses industry pain points through technological innovation and scale production. For Enoxaparin Sodium price control, Jiulong adopts advanced enzymatic hydrolysis technology—shortening production cycle from 14 days to 72 hours and reducing unit cost by 28% —while building dual raw material supply networks to avoid price fluctuations caused by resource shortages. There are no hidden fees in Jiulong’s Enoxaparin Sodium price system, with clear breakdowns of production, testing and logistics costs in contracts.

　　While ensuring Enoxaparin Sodium price stability, Jiulong maintains strict quality control over Dalteparin Sodium. The product fully complies with Chinese Pharmacopoeia, USP and EP standards, with molecular weight distribution strictly controlled to ensure balanced efficacy and safety—effectively reducing bleeding risks compared to traditional anticoagulants. Every batch of Dalteparin Sodium undergoes multi-stage testing, including bioactivity assay, heavy metal residue detection and sulfate content analysis, to eliminate clinical risks. Jiulong’s dual-product production line enables synchronized supply of Enoxaparin Sodium and Dalteparin Sodium, helping buyers reduce procurement costs and improve supply efficiency.

　　Leveraging its integrated global supply chain network, Jiulong has established stable cooperation with partners in over 50 countries and regions, including Europe, Southeast Asia and the Middle East. With an annual LMWH production capacity of over 360 million doses, the company can meet the surging demand for both Enoxaparin Sodium and Dalteparin Sodium. Jiulong also provides customized procurement solutions—flexible order volumes, personalized packaging and professional technical support—to meet the diverse needs of distributors, hospitals and research institutions. This customer-centric strategy has earned Jiulong a solid reputation in the global anticoagulant market.

　　Whether you are seeking stable Enoxaparin Sodium price, high-quality Dalteparin Sodium, or integrated dual-product supply solutions, Jiulong’s professional services and reliable products will help you seize opportunities in the booming LMWH market. For inquiries about Enoxaparin Sodium price details, Dalteparin Sodium specifications or customized cooperation plans, please contact us directly. Let’s work together to enhance global VTE prevention and control and create greater value for public health with cost-effective anticoagulant solutions.